Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05
Source: Can Commun Dis Rep - Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
More News: Antiviral Therapy | Canada Health | Coronavirus | Covid Vaccine | COVID-19 | Infectious Diseases | Intensive Care | Norvir | Statistics | Study | Vaccines